[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351837-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351837-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","sumoylation-of-ephb4-enhances-its-stability-in-prostate-cancer","SUMOylation of EphB4 enhances its stability in prostate cancer","","Receptor tyrosine kinase EphB4 is frequently overexpressed in epithelial cancers, including prostate cancer, where SUMOylation can modulate protein interactions, localisation and stability. This study examines how SUMOylation regulates EphB4 localisation, stability and function in prostate cancer cells. Analyses using siRNA and chemical inhibition, EphB4 K616R expression, and proteasomal inhibition link K616 SUMOylation to enhanced EphB4 stability, MYC signalling, and cell migration.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/sumoylation-of-ephb4-enhances-its-stability-in-prostate-cancer/351837/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/sumoylation-of-ephb4-enhances-its-stability-in-prostate-cancer/351837.png","ImageObject",300,407,{"name":42,"@type":43},"Elsa","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main biological question addressed in this study?","Question",{"text":63,"@type":64},"How SUMOylation regulates EphB4 localisation, stability, and function in prostate cancer cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which SUMOylation event is critical for EphB4 stability?",{"text":68,"@type":64},"SUMOylation at K616 is critical for EphB4 stability; the K616R mutant is degraded by the proteasome.",{"name":70,"@type":61,"acceptedAnswer":71},"How does altered EphB4 stability affect prostate cancer cell behaviour?",{"text":72,"@type":64},"Proteasome-mediated degradation of K616R is associated with reduced MYC protein levels and slower cell migration.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351837,1790332009,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","[www.nature.com/bjc](www.nature.com/bjc British)[ British](www.nature.com/bjc British) Journal of Cancer  \nARTICLE OPEN   \nCellular and Molecular Biology  \nSUMOylation of EphB4 enhances its stability in prostate cancer  \nMohanan Sada Nand Maharaj 1,2, Inga Mertens-Walker2, Jessica E. Lisle2, Adrian Herington2, Carson Stephens2, Melissa Chai2, Wim Meutermans1 and Sally-Anne Stephenson 1,2 ✉  \n© The Author(s) 2026  \nBACKGROUND: The receptor tyrosine kinase EphB4 is frequently overexpressed in epithelial cancers, including prostate cancer (PCa) . SUMOylation is a post-translational modiﬁcation that inﬂuences protein interactions, localisation and stability. This study investigated how SUMOylation regulates EphB4 localisation, stability and function in PCa.  \nMETHODS: EphB4 SUMOylation was analysed in PCa cell lines and its contribution to stability assessed using siRNA or chemical inhibition of SUMOylation. An EphB4 mutant protein (K616R) was expressed in PCa cells and proteasomal inhibition was used to assess its stability. Cell migration was measured using a scratch wound assay. Immunoprecipitation was used to determine if mutant EphB4 could be SUMOylated on other residues.  \nRESULTS: EphB4 in PCa cells is constitutively modiﬁed by SUMO2/3 and acquires SUMO1 modiﬁcation when stimulated withephrin-B2 ligand. SUMOylation of K616 is critical for EphB4 stability. K616R EphB4 protein is degraded by the proteasome, and this is associated with reduced MYC protein and slower migration. Immunoprecipitation revealed that additional SUMOylated lysines may also contribute to EphB4 function.  \nCONCLUSIONS: SUMOylation at K616 stabilises EphB4, promotes MYC signalling and PCa cell migration. These ﬁndings identify a novel mechanism regulating EphB4 and highlight SUMOylation as a potential target in EphB4-driven cancers.  \nBritish Journal of Cancer (2026) 135:48–59; [https://doi.org/10.1038/s41416-026-03442-w](https://doi.org/10.1038/s41416-026-03442-w)  \nINTRODUCTION  \nIn 2022, prostate cancer was estimated to become the fourth most common cancer worldwide and the second most common cancer in men, with more than 1.4 million new cases diagnosed [1] . The 14 Erythropoietin-producing hepatocellular (Eph) receptors constitute the largest subfamily of receptor tyrosine kinases (RTKs) [2] . Over-expression, loss of cell-cell contacts and Eph mis-localisation facilitate non-canonical signalling that has been widely associated with tumour promotion [3] . Several Eph receptors have been linked to prostate cancer, including EphB4, which is overexpressed in 66% of prostate cancer tissues, where it contributes to signalling pathways associated with viability, migration and invasion [4–9] . EphB4 expression appears to be induced by loss of tumour suppressors p53 and PTEN, inactivating mutations of which are also linked to prostate cancer initiation [7, 8] . EphB4 expression is also inﬂuenced by the PI3K signalling pathway [9] while exogenous over-expression of EphB4 in established prostate cancer cell lines leads to a more aggressive phenotype [10] .  \nKnockdown experiments using in vivo PC3 xenografts show that EphB4 is required for the continued growth of established tumours [7] . More recently, EphB4 inhibition has been linked to activation of cell death pathways that also increased cell surface localisation of calreticulin, and release of HMGB1 and ATP, all changes associated with immunogenic cell death, suggesting an effective treatment for  \nEphB4-positive tumours might be achieved by combining EphB4-targeted drugs with an immune checkpoint blockade [8] . An array of compounds, including small molecule kinase inhibitors, antibodies and both ligand mimetic and antagonistic peptides, have been developed, but the role of EphB4 in cancer is complicated with receptor clustering, bidirectional signalling having both tumoursuppressing and tumour-promoting activities and functions that are ligand-dependent, ligand-independent, kinase-dependent and kinase-i","cbCaibziN714Cl7F","https://ap.wps.com/l/cbCaibziN714Cl7F","pdf",6045517,12,"English","# Background\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What is the main biological question addressed in this study?\",\"answer\":\"How SUMOylation regulates EphB4 localisation, stability, and function in prostate cancer cells.\"},{\"question\":\"Which SUMOylation event is critical for EphB4 stability?\",\"answer\":\"SUMOylation at K616 is critical for EphB4 stability; the K616R mutant is degraded by the proteasome.\"},{\"question\":\"How does altered EphB4 stability affect prostate cancer cell behaviour?\",\"answer\":\"Proteasome-mediated degradation of K616R is associated with reduced MYC protein levels and slower cell migration.\"}]","SUMOylation of EphB4 enhances its stability in prostate cancer | PDF",1790096259,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f460add3a3070e2dde2d9aa0c13a4235.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b05f871541e5e056478e579a808eec42.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/89e2780b75cfb17948791a025acd0d27.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73d91c191399dfa39755e6fe9012a300.webp",980,1301]